论文部分内容阅读
目的:探讨复发/难治急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)患者可溶性耐药相关钙结合蛋白(sorcin)基因的表达及其与缓解率的关系。方法:采用Northern blot检测K562/A02细胞株sorcin基因表达,逆转录聚合酶链反应检测42例ALL患者、27例非白血病患者和健康人sorcin基因的表达水平,并分析sor-cin基因表达的临床意义。结果:ALL初诊组、缓解组和复发/难治组sorcin基因表达均明显高于对照组,t值分别为5.736、4.624和6.800,P值均<0.01。复发难治组sorcin基因过度表达明显高于初诊组和CR组,χ2=8.464,P=0.01。ALL患者临床耐药组sorcin基因阳性表达显著高于非临床耐药组,χ2=9.212,P<0.01;CR率非临床耐药组显著高于临床耐药组,χ2=41.28,P<0.01。结论:sorcin基因过度表达与ALL患者临床耐药密切相关,是影响预后的重要因素,可作为检测临床耐药和判断预后的指标之一。
Objective: To investigate the expression of sorcin gene in patients with relapsed / refractory acute lymphoblastic leukemia (ALL) and its relationship with remission rate. METHODS: The expression of sorcin gene in K562 / A02 cell line was detected by Northern blot. The sorcin gene expression in 42 ALL patients, 27 non-leukemia patients and healthy individuals was detected by reverse transcription polymerase chain reaction. The clinical significance of sorcin gene expression significance. Results: The sorcin gene expression in newly diagnosed group, remission group and relapsed / refractory group was significantly higher than that in control group (t = 5.736, 4.624 and 6.800, respectively, P <0.01). The over-expression of sorcin gene in relapsed and refractory cases was significantly higher than that in the newly diagnosed group and the CR group (χ2 = 8.464, P = 0.01). The expression of sorcin gene in ALL group was significantly higher than that in non-clinical group (χ2 = 9.212, P <0.01). CR rate in non-clinical group was significantly higher than that in clinical group (χ2 = 41.28, P <0.01). Conclusion: The overexpression of sorcin gene is closely related to clinical drug resistance in ALL patients and is an important factor affecting prognosis. It may be used as an indicator of clinical drug resistance and prognosis.